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Background: Chondrosarcoma is the second most common primary sarcoma of bone. High-grade conventional
chondrosarcoma and dedifferentiated chondrosarcoma have a poor outcome. In pre-clinical research aiming at the
identification of novel treatment targets, the need for representative cell lines and model systems is high, but
availability is scarce.
Methods: We developed and characterized three cell lines, derived from conventional grade III chondrosarcoma
(L835), and dedifferentiated chondrosarcoma (L2975 and L3252) of bone. Proliferation and migration were studied
and we used COBRA-FISH and array-CGH for karyotyping and genotyping. Immunohistochemistry for p16 and p53
was performed as well as TP53 and IDH mutation analysis. Cells were injected into nude mice to establish their
tumorigenic potential.
Results: We show that the three cell lines have distinct migrative properties, L2975 had the highest migration rate
and showed tumorigenic potential in mice. All cell lines showed chromosomal rearrangements with complex
karyotypes and genotypic aberrations were conserved throughout late passaging of the cell lines. All cell lines
showed loss of CDKN2A, while TP53 was wild type for exons 5–8. L835 has an IDH1 R132C mutation, L2975 an
IDH2 R172W mutation and L3252 is IDH wild type.
Conclusions: Based on the stable culturing properties of these cell lines and their genotypic profile resembling the
original tumors, these cell lines should provide useful functional models to further characterize chondrosarcoma
and to evaluate new treatment strategies.
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Chondrosarcoma is a malignant bone neoplasm character-
ized by the deposition of a hyaline cartilaginous extracellu-
lar matrix. With an incidence of 1:50,000 it typically occurs
in adults in their 3rd to 6th decade of life. Chondrosarcoma
represents a heterogeneous group of tumors. Primary cen-
tral chondrosarcoma is defined by the formation of hyaline
cartilage with decreasing matrix production in higher
grades and constitutes about 80% of all chondrosarcomas* Correspondence: j.v.m.g.bovee@lumc.nl
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distribution, and reproduction in any medium[1]. Dedifferentiated chondrosarcoma is characterized by a
low-, or intermediate grade chondrosarcoma juxtaposed to
a high grade anaplastic sarcoma and constitutes about 10%
of all chondrosarcomas [2].
Both high grade conventional and dedifferentiated
chondrosarcoma respond poorly to conventional chemo-
and/or radiotherapy, have a high metastatic rate, and
consequently have a very poor prognosis [3]. It is because
of these features that there is an urgent need for model
systems in pre-clinical research aimed at evaluating new
targeted treatment strategies for chondrosarcoma [4].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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conventional central and dedifferentiated chondrosarco-
mas [5]. IDH1 and IDH2 mutations are well known in
gliomas [6], but are notoriously difficult to grow in cul-
ture [7]. This is a feature shared by, in particular, grade I
chondrosarcomas. Recently, a new cell line derived from
a grade II chondrosarcoma was published, CH-3573 [8].
Over the last years, cell lines derived from dedifferen-
tiated chondrosarcomas have been developed [9,10]. In
the pursuit of expanding the panel of cell lines we have
succeeded in creating three new chondrosarcoma cell
lines. L835 is derived from a grade III conventional
chondrosarcoma, while L2975 and L3252 originate from
dedifferentiated chondrosarcomas of bone. These three
new cell lines provide a valuable addition to the current
panel of chondrosarcoma cell lines.
Methods
Culture of human chondrosarcoma cells
Tumor-tissue derived from three resected specimens
derived from one conventional and two dedifferentiated
chondrosarcomas were used for culture. Samples were
coded and all procedures were performed according to
the ethical guidelines “Code for Proper Secondary Use
of Human Tissue in The Netherlands 2002” (Dutch
Federation of Medical Scientific Societies http://www.
federa.org/sites/default/files/bijlagen/coreon/codeproper-
secondaryuseofhumantissue1_0.pdf). Specimens were
washed 3x with RPMI1640 (Gibco, Invitrogen Life-
Technologies, Scotland, UK) containing 1% penicillin/
streptomycin (100U/mL), minced with razor blades
and immersed in collagenase dispase overnight. After
washing, the cells were transferred into small collagen-
coated culture flasks and cultured in RPMI1640 supple-
mented with 20% heat inactivated Fetal Calf Serum
(Gibco, Invitrogen Life-Technologies, Scotland, UK),
1% L-glutamax, and 1% penicillin/streptomycin (100U/
mL). Cells were grown in a humidified incubator with
95% air and 5% CO2 and cultured until stably
multiplying.
COBRA-Fluoresence in-situ hybridization
COBRA-FISH on metaphase slides was performed as
described previously [11]. For each cell line several cell
culture passages were studied (L835: passage 17 and 35,
L2975: passage 20 and 30, L3252: passage 7, 8, and 20)
and karyotypes were described for each cell line accord-
ing to the International System of Human Cytogenetic
Nomenclature (ISCN) 2009.
Expression of cartilaginous genes
RNA was isolated from L835 (passage 40), L2975 (pas-
sage 58), and L3252 (passage 21). Chondrogenicphenotype was assessed using RT-PCR for collagen I,
IIB, III, and X, aggrecan, and SOX9 as described previ-
ously [12].
Assessment of cell line identity
DNA isolation from cell pellets was performed using
the wizard genomic DNA purification kit (Promega,
Madison, WI) according to manufacturer’s instructions.
DNA concentrations were measured using a Nanodrop
ND-1000 spectrophotometer and quality was checked on
a 1% agarose gel stained with ethidium bromide. Identity
of cell lines was confirmed using the PowerPlexW 1.2
system (Promega Benelux BV, Leiden, The Netherlands).
For L835 passage 36 was compared to primary tumor tis-
sue, for L2975 passage 37 was used, and for L3252 passage
20 was compared to primary tumor tissue.
Doubling time and migration assays
The RTCA xCelligence system (Roche Applied Sciences,
Almere, the Netherlands), based on cell-electrode sub-
stract impedance detection technology [13], was used for
doubling time and migration assays. Prior to starting
experiments cell number curves were run to determine
optimal growth curves and for doubling time experi-
ments cell lines were plated at a density of 1,000 cells
per well for L2975 and L3252 and 10,000 cells per well
for L835 in growth medium (10% FCS in RPMI1640).
For migration experiments, 100,000 cells were optimal.
For doubling time assays, 30 minutes after plating,
view-plates were loaded into the RTCA station in the
cell culture incubator. Cell index (CI) was acquired every
hour.
Proliferation was monitored for 400 hrs. Every day
plates were taken from the machine and most represen-
tative areas were photographed using a Zeiss axiovert
40C light microscope (Rijswijk, the Netherlands).
For migration assays, lower wells of the SIM plates
(migration plates) were filled with growth medium (20%
FCS in RPMI1640) as a chemoattractant, and cells were
plated in the top wells in empty buffer (RPMI1640 only).
CIM plates with 8 μm pores were loaded into the RTCA
station in the cell culture incubator immediately after
plating and cell index (CI) was acquired every 5 minutes.
Migration was monitored for 24 hrs. Experiments were
performed in triplicate.
Mutation analysis
Mutation analysis was performed for TP53 (exons 5–8)
[14], and IDH1 and −2 exons 4 [15] using direct sequen-
cing of DNA as described (14;15). Mutation analysis for
PIK3CA, KRAS, BRAF, EGFR was performed using hy-
drolysis probes assay [16] at L835 (passage 36), L2975
(passage 37), and L3252 (passage 20). Mutation analysis
for TP53 was performed at those same passage numbers
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sage 38 and 47, L2975 passage 31 and 46, and L3252
passage 20, as well as on DNA obtained from CH-3573
[8]. To determine expression of the IDH mutated alle-
le cDNA was generated using 1 μg total RNA as descri-
bed [12] for L835 (passage 38), L2975 (passage 31), and
L3252 (passage 20). Primers were designed with pri-
mer3 software (http://frodo.wi.mit.edu/primer3/) and
ordered from ISOGEN Bioscience BV (Maarssen, the
Netherlands). PCR was done with the quantitative PCR
core kit for SYBR green I supplemented with fluorescin
(Eurogentec, Seraing, Belgium) on 0.2μL cDNA per re-
action in an iCycler iQ Real-time Detection system
(Bio-Rad Laboratories, Hercules, CA). PCR was done for
40 cycles. PCR products were purified using QIAquick
PCR purification Kit (Qiagen, Hilden, Germany) accor-
ding to manufacturer’s instructions. Purified products were
sequenced by Macrogen (Amstelveen, the Netherlands)
and resulting sequences were analyzed using Mutation-
Surveyor DNA Variant Analysis software (Softgenetics,
UK). Primer sequences and annealing temperatures are
listed in Table 1.
Array-CGH analysis
Array-CGH was performed on DNA derived from the
primary tumor as well as from cultured cells of all three
cases as described [17]. DNA of L835 passage 36, L2975
passage 37, and L3252 passage 20 was used. In brief, la-
beling of 1 μg DNA was performed using the BioPrime
Total Genomic Labeling System (Invitrogen Corpor-
ation, Carlsbad, CA) following the manufacturer’s proto-
col. As reference, DNA from a commercial source
(Promega Corporation, Madison, WI) was used. Labeled
test and reference samples were mixed and hybridized as
a gender mismatch. Hybridization was performed on an
Agilent 105 k oligonucleotide array according to manu-
facturer’s instructions. Slides were scanned using theTable 1 IDH primers
Primer Tm Product
size
IDH1
genomic
Forward CGGTCTTCAGAGAAGCCATT 59.4 113
IDH1
genomic
Reverse GCCAACATGACTTACTTGATCC 58.6
IDH2
genomic
Forward AACATCCACGCCTAGTCC 56.3 90
IDH2
genomic
Reverse CAGTGGATCCCCTCTCCAC 60.5
IDH1 cDNA Forward CGGTCTTCAGAGAAGCCATT 59.4 131
IDH1 cDNA Reverse AGGCCCAGGAACAACAAAAT 56.4
IDH2 cDNA Forward AGTGTGGCTGCAAGTGTGC 60.0 365
IDH2 cDNA Reverse GAGATGGACTCGTCGGTGTT 60.1Agilent Scanner with 5 μm scan resolution. Scan images
were processed with the Feature Extraction Software
and the generated raw data files were analyzed using
Genomic Workbench (Agilent Technologies, Santa
Clara, CA). In short, the mean of the background cor-
rected and Lowess normalized log2 ratios of identical
features was calculated. Normalization of ratios was
done using the overall values as well as the values of the
control reporter probes on the array. Aberrations were
calculated using the ADM-2 algorithm with a threshold
of 8.6 and displayed with a moving average of 1 Mb.
Tumorigenicity in mice
All the experimentation involving laboratory animals
was approved by the Institutional Animal Care of Valen-
cia University and the Local Government and was per-
formed in accordance with the national legislation of
Spain. Male nude mice were purchased from IFFA-
CREDO (Lyon, France), and kept under specific
pathogen-free conditions throughout the experiments.
For each cell line, 2,000,000 cells were subcutaneously
injected in a total of 3 mice (2 months old) under sterile
conditions. Tumor was removed when size reached
4 mm in diameter and a fragment of non-necrotic
tumor, about 3 to 5 mm3 in size, was used for xenograft-
ing into two new male nude mice. The second neoplasm
was removed when the size reached 20 mm in diameter.
From each tumor a part was snap-frozen in liquid nitro-
gen, a part fixed in formalin and embedded in paraffin, a
part was used for xenografting into 2 new mice, and a
part for further culturing of post-xenograft cell lines.
(Immuno)histochemical analysis
L835 (passage 35), L2975 (passage 55), and L3252 (pas-
sage 17) cells were fixed in formalin and prepared using
the Shandon Cytoblock cell block preparation system
(Thermo Scientific, Etten-Leur, the Netherlands). Cells
were embedded in paraffin according to standard labora-
tory procedures for tissue fixation. Sections (4-μm thick)
of these paraffin blocks as well as from formalin fixed
paraffin embedded original tumor tissue and xenograft
passages, were used for H&E, toluidine blue, and immu-
nohistochemistry for ki67, p53, and p16 according to
standard procedures [18]. Details of the antibodies can
be found in Table 2.
Results
Clinicopathological data
The tissue specimen of L835 was retrieved from the re-
section specimen of the local recurrence of a chondro-
sarcoma occurring in the left distal radius (Figure 1A) of
a 54 year-old male. The primary tumor had been
resected seven months earlier. Histological examination
revealed a highly cellular cartilaginous neoplasm, with
Table 2 Antibody properties
Antibody Clone Dilution Antigen retrieval Blocking Source
p16 g175-405 1:800 Citrate - BD Pharmingen (550834)
p53 DO-7 1:800 Citrate - Dako (M7001)
Ki67 MIB-1 1:800 Citrate - Dako (M7240)
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spindle cell changes at the edge of the lobuli, consistent
with a primary central chondrosarcoma of bone, grade
III according to Evans [19] (Figure 1E).Figure 1 Radiologic and histologic examination of original tumors. A:
lytic and sclerotic lesion in the distal radius with spiculated borders (arrow)
enchondroma in the first metatarsal bone (asterisk). B: L2975 conventional
lesion (arrow) originating from the distal femur diaphysis with endosteal sc
lesion suggest osteoid matrix formation. B’: L2975 gross specimen shows in
chondrocytic and lobulated dedifferentiated compartments. C: L3252 conv
from the left chest wall with extensive rib destruction. Subtle chondroid m
suggestive for a chondrosarcoma with a higher grade of malignancy. D: Ax
the intra-abdominal component consistent with the diagnosis of chondros
staining of L2975 original tumor shows anaplastic and cartilaginous compo
of L3252 original tumor shows anaplastic and cartilaginous component (H)
p16 staining is observed in L835 original tumor, L2975 original tumor andL2975 was derived from the resection of a metastasis
of a dedifferentiated chondrosarcoma located at the
spine of a 57 year-old male. The primary tumor was
located at the right distal femur, and was originallyL835 conventional radiography demonstrates a mildly expansile mixed
and an irregular periosteal reaction. Note the presence of an
radiography shows an ill-defined expansile mixed lytic and sclerotic
alloping of the anterior cortex (asterisk). The sclerotic areas within the
tramedullar localization of dedifferentiated chondrosarcoma with
entional chest radiography shows a large lobulated mass originating
ineralization can be observed in the lesion. Radiological features are
ial CT image demonstrates chondroid mineralization (arrow) within
arcoma. E: H&E staining of high grade L835 original tumor. H&E
nent (F) and metastasis of the anaplastic component (G). H&E staining
and recurrence of the cartilaginous component (I). J-N: absence of
metastasis, and L3252 original tumor and recurrence, respectively.
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mary tumor was 13.6 cm in size and histological
examination revealed two components with a sharp
interface indicative of dedifferentiated chondrosarcoma;
a grade II chondrosarcoma was juxtaposed to a high
grade anaplastic sarcoma (Figure 1F) with focal depos-
ition of osteoid, indicating differentiation towards
osteosarcoma. Histological examination of the spine
metastasis revealed exclusively the high-grade anaplas-
tic sarcoma, in which osteoid deposition was absent
(Figure 1G).
L3252 is derived from the local recurrence of a chon-
drosarcoma located at the chest wall (costa) (Figure 1C,
D) that had already metastasized to the spine and the
lung at the time of first presentation. The primary tumor
of this 52 year-old female demonstrated a cellular, partly
myxoid and necrotic cartilaginous tumor, with mitoses,
indicative of a grade III chondrosarcoma (Figure 1H).
However, at local recurrence eight months later, areas of
a cartilaginous tumor were intermingled with an ana-
plastic sarcoma lacking differentiation, indicating dedif-
ferentiated chondrosarcoma. The tissue used for cell
culture was derived from an area in which dedifferen-
tiated areas were absent (Figure 1I).
Establishment of cell lines and transmission light
microscopy
L835 was passaged routinely in vitro for 50 generations,
L2975 for 60 generations, and L3252 for 30 generations.
The cell lines derived from dedifferentiated chondrosar-
coma (L2975 and L3252) were noticeably easier to cul-
ture than the L835 cells. This was also reflected by Ki-67
staining on embedded cells, with proliferation rates of
~60% (L835) versus ~100% and ~80% for L2975 and
L3252, respectively. The dedifferentiated chondrosar-
coma cells were less susceptible to changes in culture
conditions reflecting their more aggressive nature.
Transmission light microscopy revealed L2975 cells to
retain their elongated morphology when in confluence
and L3252 cells to detach when reaching confluence
(Figure 2A). Identity of cell lines was confirmed using
the PowerPlexW 1.2 system (Promega Benelux BV, Leiden,
The Netherlands). L835 passage 36, L2975 passage 37,
and L3252 passage 20 showed identical STR loci when
compared to their matching original tumors. Data are
available on request. qPCR for expression of cartilage mar-
kers revealed expression of ColI, ColIII, aggrecan, and
SOX9 in L835 cell line. L2975 cell line expressed ColI,
ColIII, ColX, and SOX9. L3252B cell line expressed ColI,
ColII, ColIII, ColX, aggrecan, and SOX9.
Migration
All cell lines were able to migrate. Migration for L835
was at the same rate as cell attachment in theproliferation assay (Figure 2B). For L2975, cell migration
occurred much more rapidly than cell attachment
(Figure 2C). Moreover, due to high migration efficiency,
and the fact that more cells were applied in the migra-
tion assay, the cell attachment percentage exceeds that
of which is achieved in the proliferation assay. For
L3252 cells, migration was observed but only for a small
percentage of cells (Figure 2D).Transplantation into nude mice
L2975 cells were subcutaneously transplanted into
nude mice and a tumor of 4 mm in diameter was
observed in 1 out of 3 mice after 3 months. A frag-
ment of the resulting tumor was subsequently subcuta-
neously transplanted into 2 nude mice and a tumor of
20 mm in diameter was observed in 2 out of 2 mice.
Morphologically, tumor cells of both the first and sec-
ond xenograft showed a more epithelioid morphology
(Figure 3A, B) while no deposition of cartilaginous
matrix was observed at H&E or Toluidine Blue stain-
ing (results not shown). Immunohistochemistry showed
that 90% of cells of both xenografts were positive for
Ki-67 and were thus actively proliferating (results not
shown). Cells obtained from both xenografts were suc-
cessfully passaged. Xenografting of L835 and L3252
did not result in tumors in 8 months.COBRA-Fluorescence in-situ hybridization
The cell line L835 showed a stable karyotype
(Figure 4A’). There were many numerical changes
with some translocations. The resulting karyotype at
passage 35 was: 63-67< 3n>,XY,-X,+Y,+der(1;19)t(1;19)
(p11;p13.3)trp(19)(p13.3p13.2),der(1;19)t(1;19)(p11;p13.3)
trp(19)(p13.3p13.2),-3,-4,+5,-6,+7,-8,-9,-10,-11,+13,t(14;15)
(q22;q24),+der(15)t(14;15)(q22;q24)del(15)(q21q24),+16,-
17,i(17)(q10),-18,-19,+20,+21,-22.
L2975 also revealed a stable karyotype at passage 30
with many numerical changes and complex rearrange-
ments (Figure 4B’). The resulting karyotype was: 61-
65 < 3n > der(X;4)(p10;p10),der(X;8)(q10;q10),-Y,+der(Y;9)
(p10;p10)x2,+der(1;15)(q10;q10),der(1;1)(q10;q10)t(1;6)
(q21;q24)t(1;8)(q31;p11),der(1;8)(p10;p10),del(2)(q22q32),
-4,-5,+der(7;15)(q10;q10),t(9;16)(q10;q10)x2,der(10;18)
(q10;q10),-13,der(13;13)(q10;q10),der(14;15)(q10;q10)
t(8;15)(q11;q21),-15,-15,-16,-17,i(17)(q10),-18,der(18)
t(1;18)(p31;q22),der(20)t(X;20)(q23,p12),-21,+mar3x.
L3252 was stable at passage 20 with many numerical
changes and complex rearrangements (Figure 4C’):
51 <2n+>,X,-X,+der(3;11)t(3;11)(p10;q10)t(11;17) (q14;q22),
der(4;8)t(4;8)(q10;p10),der(4),+der(5),der(6;15)t(6;15)
(p10;q10), der(7)t(7;18),der(7),+der(8)x2,der(8),der(9),
der (10),+12,der(13;13)(q10;q10),-13,der(17),i(17)(p10;p10)
der(18)t(7;18),+der(20), der(21),+mar.
Figure 2 Cell morphology and migration. A: Light microscopy at 40x magnification. Top panel shows L835 cells with round nuclei do not fully
populate the flask; day 13 is representative of a full flask for this cell line. Middle panel shows L2975 showing a full flask at day 6 already,
multinucleated cells can be observed. Bottom panel shows L3252 still actively dividing, and dividing cells tend to detach and re-attach to the
bottom of the flask. B-D Migration plotted against proliferation for the first 10 hours after plating. 1,000 – 10,000 cells were used in the
proliferation assay and 100,000 cells in the migration assay. Though all cell lines show migrative capacity, L2975 cells are most successful and
have high migrative activity during the first 4 hours after which the slope flattens.
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In L835 and L2975, all aberrations present in the tumor
were retained in the cell lines. L835 showed a homozy-
gous CDKN2A deletion in both the original tumor and
the cell line (Figure 4A”). L2975 and L3252 both showed
a homozygous deletion in the cell line (Figure 4B” and
4C”), the deletion status of the primary tumor was diffi-
cult to assess due to low tumor content and conse-
quently resulting suppressed ratio profiles. For both
L835 and L2975 clear DNA copy number alterations
could be observed in the original tumor samples that
were enhanced in the cell lines. For L3252 tumor DNA
this was less pronounced. On close examination of the
profile, however, one can observe small copy numberchanges consistent with those observed in the cell line.
We previously demonstrated L835 (passage 38) to har-
bor an IDH1 R132C mutation and L2975 (passage 31)
an IDH2 R172W mutation [15]. We here show that
L3252 (passage 20) is wild type and that also later pas-
sages of L835 (passage 47) and L2975 (passage 46) retain
the IDH mutation. Using cDNA we found the mutated
IDH alleles to be expressed (results not shown). No hot-
spot mutations were detected for TP53, PIK3CA, BRAF,
KRAS, and EGFR in any of the cell lines.
Immunohistochemical characterization
Since p16 is frequently silenced in human chondrosar-
coma [18] we evaluated p16 in the original tumors, the
Figure 3 Histologic examination of xenografted L2975. A, B: H&E stainings of first and second passage of L2975 in nude mice showed L2975
cells had adapted a more rounded morphology. C: p16 staining of first passage confirmed absence of p16 expression; note positive vessel walls
(arrow).
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chemistry. All primary tumors (Figure 1J, L, M) and
recurrences (Figure 1L, N) were negative for p16. Con-
sistent with the tumor tissue, all derived cell lines lacked
p16 protein expression (Table 3), as did xenografts cre-
ated from L2975 (Figure 3C). We proceeded to test em-
bedded cells from all cell lines shown in Table 3 for p16
expression and found all to be negative. Immunohisto-
chemistry showed nuclear expression of p53 in 10-20%
of the tumor cells in L835 and L3252 primary tumor
and cell line, while L2975 tumor, cell line, and xenograft
were completely negative (results not shown).
Discussion
Chondrosarcoma is the second most common primary
sarcoma of bone and to date unresectable chondrosarco-
mas have a poor outcome [3]. Grade III and dedifferen-
tiated chondrosarcomas are extremely aggressive in
nature and there is an urgent need for model systems fa-
cilitating research in order to develop novel therapeutic
strategies. Growing chondrosarcoma cells in culture,
however, is a challenge and well growing chondrosar-
coma cell lines are sparse. We present here the establish-
ment and characterization of three new chondrosarcoma
cell lines originating from grade III and dedifferentiated
chondrosarcoma.
Recently chondrosarcoma has been found to harbor
IDH1 and IDH2 mutations (5;15) and we published that
the mutation is retained in a subset of chondrosarcoma
cell lines [15]. In glioma IDH mutations seem to be the
earliest event in gliomagenesis even before TP53 muta-
tions occur [20]. In conventional chondrosarcoma we
observe a similar phenomenon, where IDH mutations
are present already in a high percentage of low-grade
tumors and TP53 mutations are observed to increase
with grade (4;5;15). Cell lines created from IDH mutantgliomas have been reported to eliminate their IDH mu-
tation under standard culture conditions [7]. Recently,
however, a glioma cell line carrying an endogenous
IDH1 R132H mutation was published, but this cell line
showed a slow growth rate in culture [21]. We here
present three chondrosarcoma cell lines, one carrying an
IDH1 R132C mutation, one carrying an IDH2 R172W
mutation, and one wild type for IDH mutations with
stable karyotypes and steady growth patterns. These cell
lines show numerical changes and additional mutations.
We speculate that in IDH mutant chondrosarcoma the
acquisition of additional mutations as we have shown
here have facilitated their growth in culture.
The inactivation of tumor suppressor genes is a
well-known phenomenon in cancer and p16 mutations
have been reported in 20-41% of human chondrosarco-
mas [22-25]. Interestingly, all studies observed loss of
p16 to be correlated with increasing histological grade
in conventional chondrosarcoma. Recently, we showed
inactivation of p16 in 30/38 (79%) dedifferentiated
chondrosarcoma cases [26]. We previously published
three chondrosarcoma cell lines to be negative for p16
using western blot [18] and upon overexpression of
p16 using lentiviral vectors the metabolic activity and
cell viability of these cell lines was decreased, indicat-
ing loss of p16 to play a role in the proliferative cap-
acity of chondrosarcoma cells. Introduction of p16 in
the endogenously TP53 mutant HT-1080 fibrosarcoma
cell line, which was recently reported to carry an
IDH1 R132C mutation [5], also led to cell cycle arrest
and growth inhibition [27-29]. We report here three
new chondrosarcoma cell lines lacking p16 expression
based on a homozygous deletion of the CDKN2A
locus as shown by aCGH analysis, and confirmed loss
of p16 expression using immunohistochemistry. More-
over, aCGH analysis showed a copy number loss
Figure 4 COBRA-FISH and Array-CGH. A: chromosomal analysis of L835 tumor and cell line showed numerical changes. B, C: chromosomal
analysis of L2975, L3252 showed complex rearrangements consistent with the aggressive nature of dedifferentiated chondrosarcoma.
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number gain was observed in L2975 and L3252. How-
ever, mutation analysis for TP53 showed no activating
mutations in exons 5–8, and immunohistochemistry
showed no p53 overexpression. Together, our data sug-
gest that while IDH mutations are important as early
events in a subset of chondrosarcomas, additional in-
activation of p16 may be crucial for acquiring a more
aggressive phenotype.
The literature presents us with 5 conventional chon-
drosarcoma cell lines that have been well characterized
using pathological, immunohistochemical, and molecular
genetic methods [8,30-32], and we here present L835 as
an additional cell line. We previously published L835 to
be able to form 3D pellets [33] and we now show it tobe highly stable in culture. L835 cell line showed a
slower growth rate compared to the dedifferentiated
chondrosarcoma cell lines. In all cases complex genome
alterations were observed. Dedifferentiated chondrosar-
coma is comprised of two separate components, a high
grade anaplastic component and a low to intermediate
grade cartilaginous component [2]. The histogenesis has
been under debate but evidence points to a single pre-
cursor cell with early separation of the two components
as a small number of genetic changes is identical in both
components, with additional genetic alterations in the
anaplastic component [26,34]. Indeed, 3 out of 3 dedif-
ferentiated chondrosarcomas with IDH1 mutations car-
ried the mutation in both components [26]. Moreover,
79% of the anaplastic and 82% of the cartilaginous
Table 3 Overview of chondrosarcoma cell lines and their characteristics
Cell line Tumor subtype Histological grade Passage IDH11 IDH21 p532 p163 Reference
Conventional Chondrosarcoma
SW1353 Solitary Central II p50 wt R172S V203L - ATCC
JJ012 Solitary Central II P26 R132G wt G199V - (30)
CH3573 Solitary Central II P60 wt wt T201- na (8)
CH2879 Solitary Central III P31 G105G wt wt - (31)
OUMS27 Solitary Central III P29 wt wt wt - (32)
L835 Solitary Central III p51 R132C wt wt - Present Study
Dedifferentiated Chondrosarcoma
L2975 Dedifferentiated p59 wt R172W wt - Present Study
NDCS1 Dedifferentiated P22 wt wt C242S - (9)
L3252 Dedifferentiated P26 wt wt wt - Present Study
1IDH mutations for existing cell lines were described in (15).
2p53 mutations for existing cell lines were described in (33).
3p16 mutations for existing cell lines were described in (18).
na: not available.
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and L3252 were both derived from the recurrence of a
dedifferentiated chondrosarcoma; both cell lines exhib-
ited a higher growth rate in vitro, than the L835 cell line,
but the cells in culture expressed chondrogenic markers.
L2975 proved to be the most aggressive cell line both in
culture and in our in vitro migration assay, which may
explain why this was the only cell line to be successfully
xenografted. We show here the use of L2975 dedifferen-
tiated chondrosarcoma cells with an IDH2 R172W mu-
tation in mouse models, which can be an important
asset in the research for new treatment strategies.
Conclusions
We report the establishment and molecular, genetic and
functional characterization of one grade III (L835) and
two dedifferentiated chondrosarcoma (L2975 and L3252)
cell lines. This represents a substantial addition to the
already existing panel of chondrosarcoma cell lines,
which together may reflect their heterogeneity. In
addition to the existing cell lines these cell lines present
the field with an extensive model system as heteroge-
neous in IDH1 and IDH2 and TP53 mutations as the
tumors they are derived from. This panel can be imple-
mented in studies ascertaining human chondrosarcoma
tumorigenesis, should provide useful tools in the on-
going search for new targeted therapies, and aid in
expanding our knowledge on the role of IDH1 and
IDH2 mutations in chondrosarcoma formation.
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